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Abstract 
About forty years ago the Large and small Tumor Antigens (LT-Ag and sT-Ag) of the polyomavirus 
(PyVs) SV40 have been identified and characterized. To date, it is well known that all the discovered 
human PyVs (HPyVs) encode these two multifunctional and tumorigenic proteins, expressed at viral 
replication early stage. The two T-Ags are able to transform cells both in vitro and in vivo and seem 
to play a distinct role in the pathogenesis of some tumors in humans. Additionally, they are involved 
in viral DNA replication, transcription, and virion assembly. This short review focuses on the 
structural and functional features of the HPyVs LT-Ag and sT-Ag, with special attention to their 
transforming properties.  
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Introduction 
The Polyomaviridae family has been considered capable of transforming mammals’ cells in 
vitro. In fact, since the first polyomaviruses were discovered in the 1950s, their tumorigenic 
properties observed in cell culture and animal models rendered the family name: “polyoma”- 
multiple tumors1-5. In spite of the transformative abilities of simian vacuolating virus 40 (SV40) and 
murine polyomavirus (MPyV), the human polyomaviruses BK (BKPyV)6 and JC (JCPyV)7infections 
often are asymptomatic and mostly related to non-neoplastic diseases in immunocompromised 
individuals. For instance, BKPyV has been associated to nephropathy (PVAN) in renal transplant 
recipients and hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation8-10, while 
JCPyV is the causative agent of progressive multifocal leukoencephalopathy (PML) in HIV/AIDS 
and oncologic patients, along with those under immunomodulatory therapies11,12 . 
Almost 40 years have elapsed since the discovery of the first two human polyomaviruses 
(HPyVs) until the third and fourth HPyVs identification took place, in 2007. The Washington 
University polyomavirus (WUPyV) and the Karoliska Institute polyomavirus (KIPyV) were detected 
in children with acute respiratory tract illness through molecular techniques, though their 
pathogenicity is still controversial5,13-18. In 2008, Feng et al.19, using digital transcriptome 
subtraction, identified a polyomavirus clonally integrated in about 80% of Merkel cell carcinoma 
(MCC), a rare and aggressive neuroendocrine neoplasia and hence named the virus after the cancer. 
Several other research groups confirmed the Merkel cell polyomavirus (MCPyV) presence in MCC, 
although the viral prevalence in MCC varies around the world20-34. This HPyV was the first and, so 
far, the only human polyomavirus to be etiologically related to a neoplasia in humans. Since its 
discovery, the scientific curiosity upon polyomaviruses, especially regarding their relationship to 
human cancer, has been reignited. This resulted in new researches aiming for the identification of 
HPyVs in different biological samples through new sequencing technologies35-41. Consequently, 
there are 14 proposed HPyV species, but only six of them (BKPyV, JCPyV, MCPyV, HPyV-6, 
4 
HPyV-7 and the Trichodysplasia Spinulosa- associated human polyomavirus [TSPyV]) have been 
associated with human diseases39,42,43. 
To accommodate the fast growing number of new PyVs, an update in the family taxonomy 
was published in 2016. So far, the International Committee on Taxonomy of Viruses (ICTV) 
acknowledges 73 polyomavirus species, 13 of which are HPyVs, classified in four genera, according 
to their genomic properties and natural host44. A new nomenclature was proposed, grouping HPyV in 
three genera and using the official term “Human polyomavirus” followed by the viral discovery 
order, as follows: Alphapolyomavirus genus: MCPyV or HPyV-5, TSPyV or HPyV-8, HPyV-9, 
HPyV-12, NJPyV or HPyV-13; Betapolyomavirus genus: BKPyV or HPyV-1, JCPyV or HPyV-2, 
KIPyV or HPyV-3 and WUPyV or HPyV-4; and Gammapolyomavirusgenus: HPyV-6, HPyV-7, 
HPyV-10 or MWPyV and HPyV-11 or TSPyV44. In spite of the taxonomical effort made to 
encompass all described polyomaviruses, three unclassified viruses and a recently described HPyV 
have not been classified yet41,44. 
HPyVs have a small, non-enveloped icosahedral capsid, presenting 72 pentameric capsomers 
formed mainly by VP1 associated with minor structural proteins such as VP2 and VP345-50. Viral 
genome is formed by a double-stranded, histone-associated circular DNA functionally divided into 
three main regions: a non-coding control region (NCCR), an early coding region and a late coding 
region. PyVs have bidirectional genomes and therefore, the early and late coding regions are in 
opposite strands19,51-55. Most, if not all of the PyVs transforming capacities are derived from the 
expression of the early coding region, also known as tumor antigen locus. This region codes for 
multiple spliced transcripts that, despite the variations observed among HPyVs, generates two main 
proteins: the large Tumor antigen (LT-Ag) and small Tumor antigen (sT-Ag)56-60. These two T-Ags 
are involved in the coordination of viral replication and gene expression, as well as in the cell cycle 
progress and malignant transformation both in vivo and in vitro57-65. Hence, this review presents the 
principal interactions of HPyVs T-Ag involved in tumorigenesis. 
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Human polyomaviruses Large Tumor Antigen 
The LT-Ag is a complex, multifunctional protein with many roles in viral replication and cell 
cycle progression. Due to its ability to replicate in and transform cell cultures, most of the knowledge 
about T antigens was obtained from SV40 studies66, which can be extrapolated to other PyVs55. 
Indeed, genetic and protein analyses have shown that LT-Ag virtually belonging to all HPyVs have 
several common domains: DnaJ domain; origin-binding domain (OBD); zinc (Zn)-binding domain, 
and helicase/ATPase domain55,66-68 (Figure 1, panels a-c). For viral DNA replication, six LT-Ag 
molecules interact as an hexameric structure through the recognition of three out of four 
pentanucleotide G(A/G)GGC(P1, P2 and P4) motifs in viral replication origin core, which also 
presents a highly conserved AT-rich region. This recognition is allowed by multiple and complex 
interactions between OBD, pentanucleotides motifs, GpC dinucleotides, Zn-binding domain, AT-rich 
region and histidine residues in the helicase/ATPase69-72. Two-hexameric LT-Ag unwind the viral 
genome in both directions through ATP hydrolysis, followed by the binding of the eukaryotic 
replication protein A (RPA) at the single-stranded viral DNA. The cellular topoisomerase I then 
releases the torsional stress, while alpha-primase and DNA polymerase initialize the viral DNA 
synthesis55,72-76. This replicative role of LT-Ag is frequently seen in lytic infections, and can be 
abrogated in neoplasic tissues. 
 
HPyVs integration and LT-Ag truncation 
As mentioned previously, the first HPyV associated with human cancer, MCPyV, was 
discovered clonally integrated in about 80% of Merkel cell carcinomas. The viral integration into the 
cellular genome is a well-known event that may lead to cancer through several pathways, such as 
functional loss or gain in cell cycle regulation genes, viral activation of human gene promoters, 
expression of viral oncogenes, and acquisition of mutational profile both in human or viral genes 77. 
In fact, LT-Ag premature truncation in MCC samples is considered as a MCPyV tumor-specific 
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signature, since the LT-Ag from non-tumoral samples do not harbor LT-Ag truncated forms. Hence, 
it is suggested that after MCPyV integration into the cellular genome the infected cells undergo 
selection of LT-Ag mutations to prevent viral replication and the viral Ori bidirectional unwinding, 
which would lead to collision with cellular replication forks57. In 2013, Li and colleagues78 showed 
that the intact helicase/ATPase domain activates DNA damage response, enhances p53 
phosphorylation and cell cycle arrest, which corroborates the proposed explanation for the need of 
LT-Ag truncation for MCPyV tumorigenesis. Moreover, LT-Ag truncation mutations are 
unequivocally observed downstream the pRb binding domain, occurring near to the OBD and 
helicase/ATPase domains. Therefore, a critical role for either pRb binding domain or sT-Ag 
preservation in MCC pathogenesis has been suggested 62. 
Although a strong causal association between other HPyVs with human tumors has not been 
confirmed yet, circumstantial data suggesting their transformation properties are growing. In fact, a 
recent meta-analysis revealed that the BKPyV prevalence was significantly higher in prostate cancer 
(PCa) tissues than in the control, considering as “prostate cancer tissues” samples ranging from very 
early onset of PCa to well-defined tumors and, as controls, non-PCa samples from PCa patients or 
benign prostate hyperplasia (BPH)79. There are also evidences linking BKPyV to bladder carcinoma 
in both immunocompetent80 and renal transplant recipients, as well as in urothelial and renal 
carcinomas5,77,81-83.  
Furthermore, BKPyV DNA has been found integrated into a limited number of brain tumor84, 
urothelial carcinoma85 and, more recently,  a case of renal allograft tumor77. BKPyV genome was 
found linearized and inserted into human chromosome 12 in a high-grade urothelial carcinoma from 
the allograft after almost 10 years of uneventful renal transplant. Viral genome sequencing revealed a 
new, undescribed variant of BKPyV subtype 1A, which was named Chapel Hill tumor-associated 
polyomavirus 1 (or CH-1)77. Similarly, the same group reported another undescribed variant of 
BKPyV 1A subtype, named Chapel Hill 2 (or CH-2) integrated into human chromosome 2 in a 
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poorly differentiated renal cell carcinoma83. Kenan and colleagues83 suggest that BKPyV integration 
into host genome after linearization disrupts the expression of late viral transcripts, which would 
impair LT-Ag downregulation and could eventually lead to tumorigenesis. 
Moreover, JCPyV genome has been found integrated into various brain tumors in animal 
models such as mice and owl monkeys11,86,87. Viral integration might also happen in human 
neoplasia, especially in colorectal cancer88,89, in which JCPyV is considered a co-factor for 
chromosomal instability90,91. Interestingly, most of BKPyV and JCPyV integration studies did not 
report a truncated LT-Ag. Instead, the viral genome was disrupted at the VP1 region, although 
replicative impairment has also been observed77,82,83. Nonetheless, unregulated LT-Ag expression, 
loss of late protein expression and replicative arrest occurred following viral integration83.  
Whereas the role of BKPyV integration in human oncogenesis is still hazy, MCPyV 
integration into host genomes and its involvement at least in MCC carcinogenesis have been better 
characterized. Still, the low frequency of MCPyV integration in non-MCC tumor has raised 
attention. Pantulu and colleagues92 identified LT-Ag truncation mutations in four chronic 
lymphocytic leukemia cases, which might indirectly testify the viral integration. Additionally, the 
deletion of a 90pb fragment in the MCPyV VP1 gene in non-melanoma skin cancer may also 
indicate incomplete viral integration93. Thus, the real role of low-frequency HPyVs integration into 
human cancers is yet to be established. 
HPyV LT-Ag domains for cellular proteins interaction 
LT-Ag contains several interaction domains with cellular proteins involved in cell cycle 
regulation. Some of these motifs are well conserved and most of them facilitate viral replication 
through activation of cellular proliferation and phase S entry, resulting in upregulation of enzymes 
involved in cellular DNA replication, DNA damage response and accessory replicative 
enzymes55,65,66 . Indeed, LT-Ag expression itself induces viral replication and cellular transformation 
in animal models and in cell cultures, under specific conditions62,64,66,79,91-96. The first exon of LT-Ag 
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(approximately 1-70 amino acids, shared with sT-Ag) contains the DnaJ domain, which has a 
HPDKGG (His-Pro-Asp-Lys-Gly-Gly) motif conserved among HPyV. The DnaJ domain is able to 
bind to the Hsc70, a cellular chaperone and transcriptional repressor. HPyVs ability to replicate viral 
DNA in vivo and to promote cell transformation depends on the intact DnaJ domain, as well as 
capsid assembling in vivo55,68,97-99. In fact, the MCPyV LT-Ag interaction between its DnaJ domain 
and Hsc70 has been shown to be necessary for viral replication in vitro65,68. Moreover, DnaJ domain 
binding to Hsc70 promotes the chaperone ATPase activity, generating enough energy to dissociate 
pRb/E2F55,100-102. The HPyVs BKPyV, JCPyV and MCPyV also contain a CR1 motif, formed by the 
pentapeptide LXXLL (Leu-X-X-Leu-Leu), which apparently has an auxiliary role in pRb/E2F 
disruption and cell proliferation 100,103.  
The LT-Ag linker domain is located downstream to the DnaJ domain. Almost all  HPyVs 
(JCPyV, BKPyV, WUPyV, KIPyV, TSPyV, HPyV-6, HPyV-7, HPyV-9), but not MCPyV, present a 
conserved motif WXXWW (Trp-X-X-Trp-Trp) that can bind to the Bub1, as demonstrated for SV40 
LT-Ag66,104. Bub1 is a mitotic checkpoint serine-threonine protein kinase that, when functionally 
impaired, may result in chromosomal instability, as observed in cells expressing SV40 LT-Ag105. 
Although MCPyV is oncogenic, it does not present the Bub1-binding motif. Thus, it is not 
conclusive whether Bub1:LT-Ag interaction is relevant for HPyVs transformation in vivo. Instead, at 
the nucleotide position where other HPyVs encode Bub1-binding domain, MCPyV has a sequence 
with little similarity with other PyVs, denominated unique region (MUR)65,103. MUR contains a 
minimal fragment (171–218 nucleotides), the Vam6P-binding domain, that sequestrates this 
cytoplasmatic protein to a nuclear location, resulting in lysosome clustering impairment, without 
disruption of TGF-β or mTOR signaling pathways103. The LT-Ag interaction with Vam6P seems to 
be regulatory, as its loss enhances viral replication; consequently, it is considered a mechanism for 
persistent infection establishment65,94,95. 
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Another interesting MUR interaction was observed for other known oncoviruses, such as the 
bovine papillomaviruses (BPV). Wang and colleagues 106 investigated the interaction between LT-
Ag and bromo domain protein 4 (Brd4), a member of BET family involved in cellular growth 
control, cell cycle progression, and cancer development. The Brd4 interacts with BPV’s early protein 
2 (E2) promoting the rightful partition of viral episomes to daughter cells during mitosis106,107. 
During the MCPyV infection, a similar interaction between LT-Ag and Brd4 is observed, promoting 
the MCPyV DNA replication through the cellular protein factor C (RFC) recruitment to viral Ori106. 
In addition, recent studies have shown that the human papillomavirus (HPV) are able to interact with 
Brd4, which is implicated in viral replication and E2 transcriptional activation function, since the use 
of Brd4 inhibitor reduces HPV transcription108,109. Likewise, the use of a specific peptide, named 
Brd4 410-730, which is homologous to the same region of the Brd4 but without other domains, 
successfully inhibited MCPyV replication in vitro as it disrupts Brd4:LT-Ag interaction 106.  
JCPyV LT-Ag is also able to bind the cellular beta-catenin, a cellular protein belonging to the 
Wnt pathway, important for tissue development, polarity, differentiation and cell cycle control 
through cell-cell contact. When hypophosphorylated, beta-catenin complexes with LEF-1/TCF-4 
transcription factors, and migrates to the nucleus, where it promotes cell cycle progress through c-
myc and cyclin D1 expression. Phosphorylated beta-catenin undergoes degradation via ubiquitin-
depent proteasome through the activation of a complex formed mainly by the glycogen synthase 
kinase-3 (GSK-3), Axin scaffold proteins and adenomatous polyposis coli protein (APC), which 
phosphorilates beta-catenin91,110-112 In this context, JCPyV promotes beta-catenin stabilization 
through a LT-Ag central domain, which comprehends amino acid residues from 82 to 628. Besides, 
this interaction increases beta-catenin levels and promotes its nucleic localization, with subsequent 
enhancement of c-myc expression61,113. Although the JCPyV LT-Ag:beta-catenin interaction was 
also described in mouse medulloblastoma114 and in glioblastoma cell lines115, it has been recently 
described in human colorectal carcinoma (CRC), in which beta-catenin and Wtn pathway are 
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frequently increased (Figure 2, panel c).  JCPyV LT-Ag and beta-catenin co-localization into the 
tumor cell nucleus, as well as c-myc and cyclin D1 activation in a subset of JCPyV-positive CRC has 
been described. This suggests a role of JCPyV in CRC pathogenesis, although JCPyV detection is 
frequent in both normal colorectal and CRC tissues91,116. JCPyV LT-Ag also interacts with the 
insulin-like growth factor/insulin receptor substrate 1 (IGF/IRS1) pathway, which has been proposed 
as a mechanism for malign transformation in medulloblastoma. It has been shown that JCPyV LT-
Ag binds IRS1 through its C-terminal domain117. LT-Ag:IRS1 promotes the IRS1 nuclear 
translocation,  followed by IRS1 interaction with Rad51, which indirectly and eventually prevents 
DNA damage response90 (Figure 1, panels a-c). 
Despite its recent discovery, it is already known that MCPyV is involved in different 
molecular regulatory mechanisms. For example, MCPyV detection in non-small cell lung cancer 
(NSCLC) was found to deregulate BRAF and Bcl2: the first is involved in cell cycle progression 
through MAP kinase signaling pathway, and was upregulated in MCPyV positive samples; the 
second is an anti-apoptotic mitochondrial protein that was downregulated in MCPyV infection. 
These findings were suggestive of MCPyV-mediated deregulation in NSCLC, mainly in smoker 
patients118. Furthermore, another NSCLC study reported a significant association between MCPyV 
DNA detection and LT-Ag expression with mutation on epithelial growth factor receptor (EGFR) 
mainly in non-smoker patients, supporting the hypothesis of MCPyV’s participation in a subgroup of 
NSCLC oncogenesis119.  
A similar study investigating PIK3’s mutational profile showed a higher frequency of PIK3 
mutations in MCPyV-positive MCC than in MCPyV-negative MCC, although the Akt/mTOR 
expression was higher in MCPyV-negative tumor, supporting the employment of different 
mechanisms for MCC oncogenesis in distinct MCPyV backgrounds120. Furthermore, the expression 
of tumor-derived MCPyV T-Ag in mice stratified epithelium promotes gross epithelial phenotypes, 
consistent with neoplasic progression comparable with those observed for high-grade HPV-16 E6 
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and E7 oncoproteins. Further molecular studies demonstrated the LT-Ag interaction with BIRC5 
survivin and increased E2F target gene expression, being both the pathways mediated by LT-Ag 
LXCXE motif 121.  
Finally, BKPyV LT-Ag and other HPyV LT-Ag have been recently found in the upregulation 
of the DNA cytosine deaminase APOBEC3, an important innate immune system enzyme responsible 
for suppressing viral replication and cancer. Evidences suggest that APOBEC3 may be correlated 
with cytosine-based mutation patterns and in coincident sites of DNA rearrangement. As 
APOBEC3B was also upregulated in HPV-related cancers, it is suggested that HPyV LT-Ag 
upregulation may also contribute to carcinogenesis through host genomic mutations122. 
 
HPyV LT-Ag binding with retinoblastoma protein (pRb)  
Indubitably, one of the most important LT-Ag interaction is that with retinoblastoma protein 
(pRb) family55,66 (Figure 2, panel a). This tumor suppressor family comprises three main proteins, 
pRb, p107 and p130 encoded by the RB1, RBL1 and RBL2 genes, respectively. Although the pRb 
can regulate the cell cycle through many pathways, its interaction with the E2F transcription factors 
family is one of the most important, as its loss potentiates tumorigenesis123,124. In a 
hypophosphorylated state, pRb binds the E2F transcription factor, preventing the E2F-mediated gene 
expression and thus promoting cell cycle arrest. During normal cell cycle progress,  cyclin-dependent 
kinases (CDKs) activation leads to hyperphosphorylation of serine and threonine residues at pRb 
phosphorylation-specific sites resulting in the release of the E2F transcriptional factors; their 
transcriptional activity promotes the cell cycle progress from G1 to S phase125 The components of 
the pRb family are also known as “pocket proteins”, because of a conserved “pocket” domain that 
interacts with viral oncoproteins, notoriously the SV40 LTAg and human papillomavirus E7126.  
HPyV LT-Ag, as observed in SV40 LT-Ag prototype, has a highly conserved pRb binding domain in 
its linker region. The LXCXE (Leu-X-Cis-X-Glu) motif is responsible for the LT-Ag:pRb family 
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interaction. It has been hypothesized that the energy provided by the LT-Ag  DnaJ domain binding to 
Hsc70 is used to disassociate pRb/E2F through pRb phosporilation, as corroborated by studies 
showing the DnaJ domain requirement for the SV40 LT-Ag growth activities127-129. LT-Ag is also 
capable of disrupting the transcriptional repressor complex formed by p130 and the repressive 
E2F4/5 proteins through p130 dephosporylation in a DnaJ domain dependent pathway66,91,130. The 
overall pRb:E2F disruption leads to uncontrolled cell cycle progress and, eventually, to malignant 
transformation. In fact, the pRb pathway deregulation is frequently observed in many 
tumors127,128,131. 
The SV40 LT-Ag interactions with pRb, p107 and p130 cause well known transformative effects in 
cell culture and animal models and have been recently reviewed66. However, HPyV LT-Ag also 
mediated cell transformation through pRb family binding. For instance, JCPyV LT-Ag binds the 
hypophosphorylated pRb in hamster glioblastoma cells and this interaction suppression successfully 
disables cell transformation, though JCPyV LT-Ag might be less efficient in cell transformation than 
SV40 LT-Ag132. Moreover, JCPyV LT-Ag might alter pRb expression pattern and cellular 
distribution in mouse primitive neuroectodermal tumors (PNET) and human medulloblastoma 
(HMB) cell lines, suggesting a cell-type specific LT-Ag-mediated tumorigenesis133.  
BKPyV LT-Ag can significantly reduce pRb, p107 and p130 levels and increase 
transcriptionally active E2F, requiring intact LT-Ag DnaJ and pRb binding domains in order to 
induce cell cycle deregulation101,134. Furthermore, BKPyV LT-Ag interaction with pRb and 
consequent E2F release leads to DNA methyltransferase 1 (DNMT1) gene expression, one of E2F 
target genes135. This enzyme adds methyl residues on cytosine located 5' to guanosine and is 
involved in cellular expression control, as methylation significantly reduces gene transcription 135. 
Thus, DNMT1 expression promoted by BKPyV LT-Ag probably induces the inheritable silencing of 
tumor suppressor genes, and might contribute to carcinogenesis135.   
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Likewise, MCPyV LT-Ag contains LXCXE motif and interacts with pRb family proteins57. 
In fact, this natural interaction is the decisive evidence for LT-Ag tumorigenesis pathway through 
pRb family, as pRb-binding domain is systematically maintained in MCPyV-positive MCC while the 
LT-Ag C-terminal is truncated 57. Moreover, truncated LT-Ag is more efficient in transforming cells 
then full-length LT-Ag, mainly due to its LXCXE motif and to the disruption of the C-terminal 
region inhibitory activity on cell growth94. The MCPyV LT-Ag C-terminal inhibitory activity on cell 
growth might be mediated by the phosphorylation of a LT-Ag serine residue at the position 816, 
stimulated by the ATM pathway activation. This phosphorylation site might represent a negative 
selection mechanism to eliminate functional and growth-inhibitory C-terminal during tumorigenesis, 
which also preserves pRb domain136. In vitro studies showed that the ablation of MCPyV LT-
Ag:pRb would lead to tumor regression, suggesting that the LT-Ag:pRb interaction is critical for cell 
proliferation and sustained tumor growth137. Also, a new interaction for MCPyV LT-Ag was 
observed when Arora et al.138 found that the cellular oncoprotein survivin BIRC5a, an anti-apoptotic 
protein, was seven fold more expressed in MCPyV positive MCC than in MCPyV negative MCC. 
This study also identified the need for an intact pRb binding domain for the direct LT-Ag binding to 
BIRC5a gene promoter and hence proposed the survivin as a therapeutic target for MCC137. 
However, it was already known that the HPyV LT-Ag:survivin interaction might promote cell 
survival, as observed in oligodendrocyte and astrocyte cell lines infected in vitro and expressing LT-
Ag91. 
The LT-Ag:pRb interaction has also been studied in the newly discovered HPyVs. The 
TSPyV LT-Ag mediates cells cycle progression in trichodysplasia spinulosa cases through pRb 
interaction. Kassem et al.139 showed evidences of TSPyV LT-Ag clusters with phosphorylated pRb 
by histological immunofluorescence, and concluded that LT-Ag:pRb may induce cell proliferation as 
a potential driver of papule and spicule formation. In contrast, the MWPyV LT-Ag is less stable and 
has not been yet associated to transforming abilities in vitro, although it is able to bind to pRb, p107 
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and p130139,140. Likely, HPyV-7 LT-Ag expression in thymic epithelial tumors does not correlate 
with pRb expression141, although HPyV detection and expression in thymomas was relatively 
frequent (62%) 142.  
 
HPyV LT-Ag binding with p53  
Finally, another important LT-Ag interaction in HPyV mediated tumorigenesis is that with 
p53, a tumor suppressing protein that regulates the gene expression in response to stressful events 
such as DNA damage, leading to cell apoptosis, cell cycle arrest or senescence, and is usually 
deregulated in cancer143. PyVs LT-Ag contain a p53 binding site on the helicase/ATPase domain. 
During SV40 carcinogenesis, LT-Ag binds and blocks p53 activity, preventing apoptosis and cell 
cycle arrest, induced by DNA damage, derived from pRb:E2F disruption. Instead of inducing p53 
degradation through ubiquitinase, as seen for HPV E6 protein, SV40 LT-Ag stabilizes p53, which is 
sufficient for the abrogation of its transcriptional activities66 (Figure 2, panel b).  
 BKPyV LT-Ag also complexes with p53 and, in BKPyV positive renourinary tumors, such 
association is considered an important oncogenic mechanism. The complex formation also promotes 
p53 kidnapping to cytoplasm, which is observed in both infected and transformed cell lines. Even if 
the sequestration is not a requirement for p53 inhibition, the p53 cytoplasmic accumulation 
correlates with an increased cellular mutational profile in LT-Ag expressing cells, and has been 
considered the main hallmark of BKPyV involvement in prostate cancer development143. 
Additionally, the preservation of the LT-Ag:p53 binding domain observed in tumors with BKPyV 
integration is suggestive for the LT-Ag:p53 mediated oncogenesis.  
In the same way, as observed for the p53 cytoplasmic sequestration mediated by BKPyV LT-
Ag, JCPyV LT-Ag is able to alter p53 expression and its cellular distribution in PNET and HMB cell 
lines133. A recent study conducted on paraffin embedded specimens reported a dramatic decrease in 
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p53 expression in JCPyV-positive glioblastomas when compared to JCPyV-negative gliobastomas, 
suggesting a potential role of JCPyV LT-Ag in p53 expression modulation and tumorigenesis144. 
Nevertheless, MCPyV mediated MCC tumorigenesis does not require p53 inactivation. In fact, p53 
disruption in MCC is MCPyV LT-Ag independent, as demonstrated by Houben et al.145 This 
experimental study corroborates with other previously published papers, showing that the C-terminal 
region of MCPyV LT-Ag mediates cell cycle progress inhibition94, and that the truncated LT-Ag has 
a higher transformation potential compared to the full-length LT-Ag62. Finally, these findings are 
consistent with the MCPyV tumor-specific signature in MCC, where the truncated LT-Ag lacks the 
Helicase/ATPase and p53 binding domain57.  
 
Human polyomaviruses small T antigen 
The small T antigen (sT-Ag) is another PyV protein with cell transformation properties. 
Although sT-Ag expression is not always a condition for viral replication or transformation, it is 
required for PyVs optimal functioning68,146. The SV40 sT-Ag is functionally comparable to HPV E7, 
in such a way that E7 is capable of successfully replace sT-Ag functions in vitro147. The PyV sT-Ag 
are encoded in the early region of PyVs genomes, superposed to the LT-Ag coding sequence. 
Produced by an alternative splicing of this region, sT-Ag shares about 80 amino acids in its N-
terminus with LT-Ag55. Therefore, the sT-Ag presents the DnaJ domain with a conserved HPDKGG 
motif among all HPyV, which potentially affects viral replication, cell proliferation and 
transformation, although the functional importance of this domain for sT-Ag activity is 
unknown65,148-150. The BKPyV, JCPyV and SV40 sT-Ag share high amino acid similarities with each 
other, especially on the N terminus, although the sT-Ag middle region is more divergent among 
HPyVs 151, and its hydrophobicity and flexibility are important for sT-Ag functionality 152.  
The sT-Ag transcript also contains a unique region, removed from LT-Ag during the intronic 
processing, which may have distinct features among HPyVs. For instance, JCPyV sT-Ag contains a 
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LYCKE and a LHCWE motif and BKPyV has only one LYCKE motif. Thus, these LXCXE motifs 
are potentially able to interact with pRb family proteins, whereas MCPyV sT-Ag does not present 
any LXCXE motif, as well as the other HPyVs.55,153. Regardless, all HPyVs sT-Ags have two 
conserved domains at their unique C-terminus region: two zinc-binding domains (Cys-X-Cys-X-X-
Cys motif), which provide structural and functional stability for sT-Ag, and two domains for 
phosphatase 2A (PP2A), rich in cysteine and proline residues responsible for sT-Ag:PP2A 
interaction, that require the sT-Ag DnaJ domain and the second zinc-binding motif55,151 (Figure 3, 
panels a-c). 
 
HPyV sT-Ag binding with PP2A 
The PP2A is a serine-threonine phosphatase that regulates, among many other important 
cellular processes, the cell cycle progression and apoptosis by dephosphorylating protein targets such 
as Akt, p53, c-Myc and β-catenin, and hence is considered a tumor suppressing protein. PP2A is 
composed by catalytic (PP2Ac), scaffold (PP2AA) and regulatory subunits (PP2AB), that interact to 
form an active enzymatic complex154. The SV40 sT-Ag prototype has a cysteine-proline rich and 
conserved domain (Cys-X-X-X-Pro-X-Cys) that interacts with PP2A,  mainly through the sT-Ag 
cysteine residues55,151 In fact, the ablation of only one cysteine from CXXXPXC motif dramatically 
reduces sT-Ag:PP2A binding rate155. The sT-Ag interacts with the PP2AA (scaffold) subunit by the 
HEAT repeats3-7, displacing the PP2AB (regulatory) subunit, that also binds HEAT repeats 3-7, and 
thus inhibiting PP2AAc phosphatase activity152 (Figure 4, panel a-b). 
The sT-Ag:PP2A interaction triggers several pathways related to cellular transformation. The 
entry on cell cycle S phase may be stimulated by sT-Ag:PP2A, as PP2A no longer dephosphorylates 
the cyclin-dependent kinase (CDK) inhibitor p27, leading to its degradation. Additionally, sT-
Ag:PP2A also induces the phase S entry by promoting cyclin A/CDK2 and cyclin E/CDK2 
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expression through a cell cycle regulated E2F site156,157. Furthermore, sT-Ag:PP2A has been linked 
to human fibroblast transformation by  CDK2 activation and DNA synthesis induction158.  
The SV40 sT-Ag:PP2A interaction might induce oncogenesis in vitro through the activation 
of the MAP kinase cascade159. The mitogen-activated protein kinases (MAPK) are involved in cell 
proliferation via the ERK1 and ERK2 (extracellular signal related kinases 1 and 2) upregulation of 
cyclin D1, leading to phosphorylation of pRb and the subsequent releasing of the E2F transcription 
factor. MAPK pathway activation has been linked to increased BKPyV replication in cell cultures, 
although induced by LT-Ag160. However, Wu et al.161 demonstrated that TSPyV sT-Ag 
overexpression activates the MAPK pathway by enhancing the MEK/ERK phosphorylation. Once 
more, it is suggested that sT-Ag:PP2A interaction prevents the PP2A dephosphorylation activity and 
ultimately, the suppression of  the MAPK cascade. 
It has been demonstrated that PyV sT-Ag are capable of upregulating and stabilizing the 
myelocytomatosis transcription factor (Myc), which requires intact DnaJ and PP2AsT-Ag domains. 
Studies have demonstrated that sT-Ag:c-Myc upregulation is related with later increase of human 
telomerase and cyclin D1, suggestive for Myc targeted expression162. The c-Myc and cyclin D1 
promoter activity was also increased by JCPyV sT-Ag and beta-catenin, both separated and 
associated, the latter found to potentiate the effect116. Moreover, MCPyV sT-Ag is capable of 
increasing c-Myc activity. Normally, the Fbw7 ubiquitin ligase protein complex promotes the 
degradation of proto-oncogenes products such as cyclin E, c-MYc, c-Jun, mTOR and NF-kB by a 
phosphorylation-dependent mechanism. Recent findings support the idea that the sT-Ag can inhibit 
the LT-Ag, c-Myc and cyclin E proteasomal degradation through their stabilization, thus regulating 
several cell cycle proliferation pathways163. 
Furthermore, human cells expressing SV40 sT-Ag have shown upregulation of anti-apoptotic 
targets of NF-kB164, despite most viral proteic interactions with NF-kB pathway have been shown to 
have inhibitory effects. For instance, MCPyV sT-Ag downregulates NF-kB by targeting the NEMO 
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adaptor protein and, thus, disrupting the inflammatory pathway165. Moreover, NF-kB regulation 
pathway by MCPyV sT-Ag involves the regulatory sub-unit 1 of the protein phosphatase 4 (PP4R1), 
which is required for NEMO adaptor protein interaction166. NF-kB has also been described as a 
promoter of JCPyV replication during DNA damage response induced by JCPyV itself167. These sT-
Ag inhibitory activities on NF-kB pathway, responsible for innate immune response, might be 
related to host immune response evasion, whose impact on tumorigenesis still remains unclear. 
 
sT-Ag/PP2A independent pathways 
Despite the principal PyVs sT-Ag oncogenic pathway is associated with the PP2A 
deregulation, MCPyV sT-Ag may be able to induce cell transformation in a PP2A independent way. 
For instance, it has been shown that MCPyV sT-Ag may induce cell proliferation depending on the 
Akt-mTOR signaling without PP2A deregulation168. The mTOR (mammalian target of rapamycin) is 
a serine threonine kinase that controls cellular functions such as transcription and translation. When 
activated, mTOR phosphorylates some translational control proteins, such as the initiation factor 4E 
binding protein 1 (4E-BP1), preventing its inhibitory activity and releasing the initiation factor 4 
(eIF4E), which may then promote translation and further cell cycle progression151. The PP2A domain 
of MCPyV sT-Ag domain is not required for epithelial transformation in transgenic mice169. 
Furthermore, it has been demonstrated that MCPyV sT-Ag is able to dislocate a restrict number of 
PP2AB subunits, which lead to a sT-Ag:PP2A interaction insufficient to promote tumorigenesis in 
vitro. Instead, MCPyV sT-Ag induces oncogenesis through the so-called large T stabilization domain 
(LSD)163,170. The LSD domain is located at residues 91-95 and inhibits MCPyV LT-Ag proteasomal 
degradation, since LT-Ag is the target for the Fbw7 E3 ubiquitin-ligase. Mutations at LSD disrupt 
LT-Ag stabilization, prevent sT-Ag cell transformation and viral replication, as well as reduce sT-Ag 
induction of cellular oncoprotein, still in a PP2A independent manner65,170. 
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Another MCPyC sT-Ag interaction related to in vitro tumorigenesis is that with c-Jun, a 
transcription factor that regulates cellular differentiation, and proliferation. When 
hyperphosphorylated, c-Jun is capable of inducing tumorigenesis, especially in keratinocytes171. A 
recent study172 observed that c-Jun hyperphosphorylation increased after MCPyV sT-Ag 
overexpression in HEK293 cell line. Additionally, although c-Jun phosphorylation status in in vivo 
MCC is currently unknown, its activation by MCPyV sT-Ag may contribute to the MCC aggressive 
pattern, thus demanding further investigations172. Finally, it has also been demonstrated that TSPyV 
sT-Ag overexpression is associated with c-Jun phosphorylation and activation, indicating a role for 
TSPyV sT-Ag in the TS pathogenesis161. 
 
Conclusions 
Indubitably, among the proteins encoded by the HPyVs, the principal agent involved in cell 
transformation and tumor development is the LT-Ag, which is also the most studied. Interestingly, 
the structure and function of this protein are quite conserved among the different HPyVs, testifying 
that it is indispensable for both viral replication and interaction with the host cells. However, this 
review underlined also the strategic role of the other early protein encoded by the HPyVs, the sT-Ag. 
Additionally, it should be taken into account that some of the classic and newly discovered HPyVs 
are also able to produce agnoprotein, which may have transforming activities itself91. Most probably, 
these proteins act synergically, orchestrated by LT-Ag,  fighting a battle against the infected host, 
trying to evade from the immune system and targeting multiple cellular pathways. To this particular 
regard, the evasion of the innate immune system by HPyV has been so far studied for MCPyV. Both 
MCPyV LT-Ag and sT-Ag, and also BKPyV LT-Ag, are able to interact with the Toll-like receptor 9 
(TLR9) and to inhibit it, causing the subsequent lack of transcription of C/EBPThis last 
transcription factor plays several roles in the suppression activity of the tumor proliferation, i.e. it 
regulates IL-6, IL-8, TNF-a and E2F expressions. Consequently, the suppression of 
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C/EBPexpression by the HPyVs T-Ag induces modification in the immune system reactions 
against the viruses and also triggers the cell proliferation173-176  
 Not all of the involved mechanisms, neither the interactions among the viral proteins have 
been fully understood and the continuous discovery of new HPyVs might favor the understanding of 
cell transformation mediated by the HPyVs.  
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Figure 1. Scheme of the functional domains of the HPyVs’ large T antigen (L-Tag). The L-Tag 
consists of several functional domains: DnaJ domain, linker domain, origin binding domain (OBD), 
zinc (Zn++)-binding domain and helicase/ATPase domain. (a) The DnaJ domain contains: a 
HPDKGG motif, conserved among HPyVs, which is able to bind to the Hsc70, a cellular chaperone 
and transcriptional repressor; a CR1 motif (LXXLL), present only in BKPyV, JCPyV and MCPyV. 
(b) The linker domain contains: WXXWW motif, conserved in the majority of HPyVs but not in 
MCPyV, for binding Bub1, a mitotic checkpoint serine-threonine protein kinase; a unique region 
(MUR), only present in MCPyV, that binds the Vamp6P-protein and the Bromodomain protein4 for 
the recruitment of cellular protein factor C (RFC); a LXCXE motif, conserved in the majority of 
HPyVs, crucial for the interaction with the retinoblastoma protein (pRb) family. (c) The 
helicase/ATPase domain comprises: a p53 binding domain, conserved in the majority of HPyVs; a 
C-terminal domain, only present in JCPyV, that binds the insulin receptor substrate 1 (IRF1). 
Figure 2. HPyVs’ large T antigen (L-Tag) oncogenic mechanisms. (a) In physiological conditions, 
the retinoblastoma proteins (pRbs) are in a hypophosphorylated state, which allows them to bind and 
inhibit the E2F transcription factors, preventing the E2F-mediated gene expression and consequently 
the transition from G1 into S phase. HPyVs’ L-Tag is able to bind the pRb proteins promoting their 
hyperphosphorylation, thus pRb is unable to bind E2F, leading to its transcriptional activity; at the 
same time the hyperphosphorylation of p130 disrupts the transcriptional repressor complex (p130-
E2F4/5), leading to uncontrolled cell cycle progression and sometimes to malignant transformation. 
(b) Multiple cellular stress, normally, raise the levels of p53, which promotes the DNA repair and 
cell cycle arrest. HPyVs’ L-Tag is able to bind and block the activity of p53 protein, preventing 
apoptosis and cell cycle arrest induced by DNA damage. (c) In physiological conditions, the 
phosphorylated β-catenin undergoes degradation via ubiquitin-dependent proteasome. JCPyVs’ L-
Tag binds the β-catenin protein promoting its hypophosphorylation, thus β-catenin complexes with 
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LEF-1/TCF-4 transcription factors, promoting the cell cycle progression by c-myc and cyclin D1 
expression.  
Figure 3. Scheme of the functional domains of the HPyVs’ small T antigen (s-Tag). The s-Tag 
presents a DnaJ domain, followed by an unique domain, that is removed from LT-Ag during the 
splicing process. (a) The DnaJ domain contains a LYCKE motif (JCPyV and BKPyV) and a 
LHCWE motif (only JCPYV), able to interact with pRb family proteins. (b) The unique domains 
contains two Zn++ binding sites and, additionally and only in MCPyV, a PPAR1/NEMO binding site 
and a large T stabilization domain (LSD), that is involved in the oncogenesis process. (c) The 
binding site for the PP2A is conserved in the majority of the HPyVs and triggers several pathways 
related to cellular transformation. 
Figure 4. HPyVs’ small T antigen (s-TAg) oncogenic mechanisms. (a) In physiological conditions, 
the Akt, p53, c-Myc and β-catenin proteins are in a phosphorylated state; the subsequent 
dephosphorilation due to the PP2A serine-threonine phosphatase regulates the cell cycle progression 
and the apoptosis process. (b) The binding between s-TAg and PP2A avoids the dephosphorilation of 
Akt, p53, c-Myc and β-catenin proteins, and the subsequent deregulation of the cell cycle 
progression and apoptosis process drives the cell to a malignant transformation.  
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